AIDS InfoNet Logo
This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

The Henry J. Kaiser Family Foundation
Site of the Week
November 2003

The Health Leader Award 2006
The Health Leader Award 2006

The HOPE Reward

Med411.com Medical Award

HealthAtoZ.com Featured Site Award

BuscaSalud.com

IBS Tales Hope Award

HealingWell.com Editor's Choice Award

Listed in Listed in Treasures of the Internet


AIDS InfoNet Logo.  The AIDS InfoNet - Reliable, Up-to-Date AIDS Treatment Information
International Association of Providers of AIDS Care
Revised April 5, 2016

Fact Sheet 404

U.S. Antiretroviral Therapy Guidelines


NOTE:
The full text of these guidelines is available on the Internet.


WHY DO THE GUIDELINES KEEP CHANGING?
VIRAL LOAD AND CD4 CELL TESTING
RESISTANCE TESTING
OTHER LABORATORY TESTS
WHEN TO START TREATMENT
GOALS OF THERAPY
WHAT DRUGS SHOULD BE USED FIRST?
FACTORS TO CONSIDER IN CHOOSING INITIAL ART
ART ADHERENCE
OTHER PARTS OF THE GUIDELINES

 


WHY DO THE GUIDELINES KEEP CHANGING?

We keep learning more about the best way to fight HIV. In 1998, the US Department of Health and Human Services created a panel of physicians, researchers, and consumers to develop treatment guidelines. They constantly review AIDS research results. The guidelines are updated at least once each year. This fact sheet reflects the guidelines as of April 2016.

NOTE: These are guidelines, not rules. Patients should receive individualized care from a health care provider with experience treating HIV infection. The full text of these guidelines is available on the Internet at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf 

 


VIRAL LOAD AND CD4 CELL TESTING

Viral load and CD4 cell tests provide critical information for decisions on antiretroviral therapy (ART). Before changing treatment, the tests should be repeated to confirm the results. Fact Sheet 124 has more information on CD4 cell tests and Fact Sheet 125 covers viral load testing.

 


RESISTANCE TESTING

Viral resistance testing helps health care providers choose the most effective drugs. See Fact Sheet 126 for more information. Resistance testing is recommended for patients starting therapy, when viral load is not controlled by new medications, or when it “breaks through” a regimen that used to work. The guidelines recommend resistance testing before starting ART. This can show if the person got infected with drug-resistant virus

 


OTHER LABORATORY TESTS

The guidelines recommend using a viral tropism test (see fact sheet 129) before starting therapy with a CCR5 inhibitor. They also suggest using a genetic test, HLA-B*5701 before starting abacavir (see fact sheet 416),

 


WHEN TO START TREATMENT

Treatment is recommended for all people living with HIV, regardless of CD4 count .

Regardless of CD4 count, treatment is strongly recommended for all pregnant patients, and patients with HIV-associated nephropathy (a kidney disorder) or those who need treatment for hepatitis B.
 


GOALS OF THERAPY

The guidelines list the following goals for HIV therapy. Treatment goals are the same for people starting therapy and those who have been on therapy for a long time:
• Reduce viral load as much as possible for as long as possible
• Restore or preserve the immune system
• Reduce sickness and death due to HIV
• Prolong the duration and quality of life
• Prevent HIV transmission

The following tools are suggested to help achieve these goals:
• Selection of initial ART
• Maximize adherence. Help the patient take medications correctly.
 


WHAT DRUGS SHOULD BE USED FIRST?

The guidelines recommended 6 ART regimens for people starting anti-HIV treatment.

Five of the six regimens use a HIV integrase inhibitor with two nukes:
Dolutegravir/abacavir/lamivudine (Triumeq)
Dolutegravir (Tivicay) + tenofovir DF/emtricitabine (Truvada)
Elvitegravir/cobicistat/tenofovir AF/emtricitabine (Genvoya)
Elvitegravir/cobicistat/tenofovir DF/emtricitabine (Stribild)
Raltegravir (Isentress) + Truvada

One regimen uses a protease inhibitor with two nukes:
Darunavir (Prezista)/ritonavir (Norvir) + Truvada

Several other combinations are categorized as “alternative” or “other” regimens, including previously recommended Atripla, Complera and atazanavir (Reyataz). These regimens have possible disadvantages compared with the recommended regimens or have less study data.


FACTORS TO CONSIDER IN CHOOSING INITIAL ART

The guidelines recommend considering pre-treatment
• Viral load
• CD4 count
• HIV resistance test results
• HLA-B*5701 status
• Patient preferences and anticipated adherence.
Selection should also consider the patient’s
• Cardiovascular disease
• Kidney and bone disease
• Mental health
• Neurologic disease
• Drug addiction treatment
• Pregnancy or pregnancy potential
• Co-infection with hepatitis B virus, hepatitis C virus and tuberculosis


ART  ADHERENCE

Taking ART correctly, every day, is critical for the medications to work; this is called adherence. The guidelines recommend involving the patient in ART selection, to assess adherence at every clinic visit, to identify the type and reasons for non-adherence. 


OTHER PARTS OF THE GUIDELINES?

The guidelines also discuss virologic failure, poor CD4 recovery, regimen switching and the discontinuation or interruption of treatment.

 



 


Back to Fact Sheet Categories



International Association of Providers of AIDS Care

 

The AIDS InfoNet is a project of the International Association of Providers of AIDS Care.
webmaster@aidsinfonet.org

 

United States National Library of Medicine

Partially funded by the National Library of Medicine



Search Our Site
Newest Fact Sheets
Print This Fact Sheet
You can print this fact sheet on a single page in Microsoft Word (.doc) format or Adobe Acrobat (.pdf) format. Click on the links below to open the document in your browser and then print it.
 Adobe Acrobat PDF
 Microsoft Word

You can print directly from your browser using the link below. The printout will probably go onto a second page.
 Print Version (Web)

Monthly E-mail Updates

The InfoNet updates its Fact Sheets frequently. A listing of each month's changes is posted to several e-mail lists.

If you would like to receive this monthly update by personal e-mail, please click on the SUBMIT button.

SUBMIT